Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Right Dosing, Scheduling Key To Anticipating Resistance, Creating Synergistic Combos In Drug Development

Executive Summary

The art of developing synergistic combinations of novel drugs that can win the race against resistance mutations was much discussed at the American Association for Cancer Research meeting in Chicago March 31 - April 4.

You may also be interested in...



Yervoy/Zelboraf Combo Trial Fails, But Sequential Study Continues

Small Phase I melanoma study testing a combination of Zelboraf and Yervoy was closed early due to an unexpectedly high rate of liver toxicity, investigators report in letter to the editor of the New England Journal of Medicine. A sequential study of Yervoy and Zelboraf and other combination studies proceed as planned.

Cyclacel Novel/Novel Sequence Promising In Tough Cancers

The combination of two novel drugs from Cyclacel inflicts a form of synthetic lethality in which sapacitabine causes DNA defects, rendering tumor cells vulnerable to seliciclib, which thwarts the repair process and is lethal in its own right, the lead investigator reported April 7 at the American Association for Cancer Research meeting in Washington, D.C.

Cyclacel Novel/Novel Sequence Promising In Tough Cancers

The combination of two novel drugs from Cyclacel inflicts a form of synthetic lethality in which sapacitabine causes DNA defects, rendering tumor cells vulnerable to seliciclib, which thwarts the repair process and is lethal in its own right, the lead investigator reported April 7 at the American Association for Cancer Research meeting in Washington, D.C.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS054363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel